Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of reduced starting dose and prophylactic management for neratinib adjuvant therapy in HER2-positive breast cancer
ChiCTR2600129511Phase 4Not yet recruiting
- Sponsor
- Xinyang Central Hospital
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of neratinib in breast cancer, sponsored by Xinyang Central Hospital. Primary endpoint: Incidence of Grade 3 or higher diarrhea during Cycle 1 (28 days). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600129511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129511.